Latest news
Jazz Pharmaceuticals to Acquire Actio Biosciences in Merger - TipRanksTipRanks · Mon, 10 Aug 2026 22:36:25 GMTJazz Pharmaceuticals: Buy Rating Reiterated as Actio Bioscience Acquisition and ABS-1230 Growth Potential Support Unchanged $307 Price Target - TipRanksTipRanks · Mon, 10 Aug 2026 17:29:04 GMTJazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio - TipRanksTipRanks · Mon, 10 Aug 2026 12:19:51 GMTPharma Mar Flags Planned Loss of Zepzelca Second-Line SCLC Indication - TipRanksTipRanks · Thu, 06 Aug 2026 02:43:29 GMTJazz Pharmaceuticals Raises Guidance on Q2 Earnings Strength - TipRanksTipRanks · Wed, 05 Aug 2026 02:35:21 GMTJazz Pharmaceuticals: Buy Rating Reaffirmed as Strong Momentum and Emerging Oncology Catalysts Drive Price Target Increase to $280 - TipRanksTipRanks · Tue, 04 Aug 2026 20:18:37 GMTJazz Pharmaceuticals: Buy Rating Reaffirmed as Strong Q2 Results, Growth Franchises, and Pipeline Upside Drive Price-Target Increase - TipRanksTipRanks · Tue, 04 Aug 2026 16:48:24 GMTJazz Pharmaceuticals price target raised to $270 from $260 at Barclays - TipRanksTipRanks · Tue, 04 Aug 2026 16:11:19 GMT